| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Opus Genetics Inc. | Nyxol Eye Drops - (MIRA-4) | Mydriasis in patients aged 3-11 | NDA Filing | Ongoing | Ophthalmic | Opthalmic |
| Opus Genetics Inc. | Nyxol + Low-Dose Pilocarpine Eye Drops - (VEGA-2/VEGA-3) | Presbyopia | Phase 3 | Data Released | Ophthalmic | Opthalmic |
| Opus Genetics Inc. | Nyxol Eye Drops - (LYNX-1) | Dim Light or Night Vision Disturbances (DLD) | Phase 3 | Ongoing | Ophthalmic | Opthalmic |
| Opus Genetics Inc. | Phentolamine ophthalmic solution - (LYNX-3) | Decreased visual acuity under dim (mesopic) light conditions | Phase 3 | Data Released | Ocular | Opthalmic |
| Opus Genetics Inc. | APX3330 Oral Pill - (ZETA-1) | Diabetic Retinopathy (DR) / Macular Edema (DME) | Phase 2/3 | Trial Planned | Oral | Opthalmic |
| Oragenics Inc. | AG013 | Oral mucositis (OM) | Phase 2 | Oral rinse | Wound Care | |
| Organovo Holdings Inc. | FXR314 | MASH & Primary Biliary Cholangitis | Phase 2/3 | Data Released | Topical | Gastroenterology |
| Organovo Holdings Inc. | FXR314 | Ulcerative colitis (UC) | Phase 2 | Enrollment Initiation | Topical | Gastroenterology |